1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Familial hypobetalipoproteinaemia (Familial hypobetalipoproteinaemia type 1).
1.2 OMIM# of the disease 615558.
1.3 Name of the analysed genes or DNA/chromosome segments APOB.
OMIM# of the gene(s)
107730.
Mutational spectrum
Over 90 variants have been reported, mostly nonsense and frameshift, occurring throughout the 29 exons of APOB. [1] [2] [3] [4] Missense variants affecting the amino terminal region of the apolipoprotein B (apoB) protein have also been described in familial hypobetalipoproteinaemia. 5 1.6 Analytical methods DNA sequencing of genomic-exonic DNA with at least 20 bp of flanking intronic sequence. Western blotting can be used to detect truncated apoB species that are 430% of full-length protein size, to estimate where the variant occurs within APOB. If western blotting is negative, sequencing of the 5' 30% of the gene (exons 1 through 25) is recommended. Where homozygous familial hypobetalipoproteinaemia is suspected and a variant(s) in APOB cannot be found, consider sequencing MTTP.
Analytical validation
Where a variant is identified using bi-directional DNA sequencing, the test should be repeated from a fresh dilution of DNA for confirmation. For homozygous familial hypobetalipoproteinaemia, testing of the patient's parents is recommended, to confirm that the two variants are present in trans (ie, on opposite chromosomes).
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence)
Approximately 1 in 1000-3000 are estimated to carry apoB truncations (heterozygous familial hypobetalipoproteinaemia). 6 1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting
Yes No
Familial hypobetalipoproteinaemia is primarily a biochemical diagnosis; heterozygotes have plasma apoB levels one-quarter to one-third of normal, while in homozygotes apoB is very low or undetectable. Prenatal diagnosis may be required by parents who are both known to carry short truncations leading to severe apoB deficiency. Many factors, such as a strict vegan diet, illness and high-dose statin therapy, can cause hypobetalipoproteinaemia. The more common secondary causes in the hospital setting include cachexia, malabsorption, malnutrition, severe liver disease and hyperthyroidism. Familial hypobetalipoproteinaemia is characterised by low levels (o5th percentile for age and sex) of plasma apoB-containing lipoproteins. 1,2 It has been suggested that familial hypobetalipoproteinaemia might represent a longevity syndrome and be associated with cardiovascular protection due to resistance to atherosclerosis. Heterozygotes are usually asymptomatic with low-density lipoprotein (LDL) cholesterol and apoB concentrations approximately one-third of those in normal plasma. Most of them have increased serum aminotransaminases due to hepatic steatosis and sometimes mild fat malabsorption.
TEST CHARACTERISTICS
Homozygous familial hypobetalipoproteinaemia is biochemically characterised by the absence of apoB-containing lipoproteins from plasma. The clinical features may resemble those of abetalipoproteinaemia: fat malabsorption, fatty liver, acanthocytosis, retinitis pigmentosa, spinocerebellar ataxia and myopathy, particularly in those with truncating variants shorter in length than apoB-48. Should this constellation of findings be present there are two possibilities, homozygous familial hypobetalipoproteinaemia or abetalipoproteinaemia caused by variants in MTTP. Family screening is useful in delineating between these conditions, as while obligate heterozygote parents of abetalipoproteinaemia patients have normal plasma lipid profiles, obligate heterozygous parents of homozygous familial hypobetalipoproteinaemia patients have plasma LDL cholesterol and apoB concentrations approximately one-third of normal.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Approximately 100%.
2.5
Positive clinical predictive value (life time risk to develop the disease if the test is positive) 100%.
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been tested: 100%. Index case in that family had not been tested: Should the constellation of clinical findings be present in an index case, it is possible that they might have abetalipoproteinaemia, rather than homozygous familial hypolipoproteinaemia. Abetalipoproteinaemia patients receive similar treatment advice as homozygous familial hypobetalipoproteinaemia patients. Also, there are even rarer conditions called homozygous proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency and familial combined hypolipidaemia (due to homozygous variants in angiopoietin-like protein 3, ANGPTL3) that present with extremely low (but not absent) levels of apoB-containing lipoproteins, but no systemic manifestations. 2 In familial combined hypolipidaemia, high-density lipoprotein (HDL) cholesterol levels are also very low. To date, there are only a handful of families in the world reported with these latter two genetic conditions. A low-fat diet (o30% of total calories) will eliminate steatorrhoea and allows absorption of other nutrients essential for growth and development. High-dose oral fat-soluble vitamins are thought to bypass the intestinal chylomicron assembly pathway via the portal circulation and are associated with improved clinical outcomes. High-dose oral vitamin E supplementation (100-300 mg/kg/day) is recommended to halt the progression of neurological disease; however, serum levels do not The impact of age at diagnosis, commencement of a lowfat diet and fat-soluble vitamin supplementation, and the findings from APOB genomic DNA sequencing in homozygous familial hypobetalipoproteinaemia are variable. Early treatment with high-dose oral vitamin E and A can reduce the potential severity of neuropathy and retinopathy. 1, 11 A relative paucity of data makes it difficut to predict outcomes based on APOB genotype.
CLINICAL UTILITY
The long-term outcome of hepatic steatosis in familial hypobetalipoproteinaemia is unknown, but associations with hepatic steatohepatitis, cirrhosis and hepatocarcinoma have been reported. 3, 7, 12, 13 Management (please describe)
The clinical follow-up and management of homozygous familial hypobetalipoproteinaemia focuses on evaluating symptoms and monitoring growth in children, detecting and preventing complications, and monitoring compliance with therapy by providing specialised dietary advice and fat-soluble vitamin therapeutic regimens. 9 Increased serum aminotransferases and hepatic steatosis are a common occurrence in heterozygous familial hypobetalipoproteinaemia; however, the long-term consequences are unknown. Therefore, it would seem prudent to monitor biochemically and by imaging techniques the livers of these individuals gven a potential increased risk of progression to cirrhosis, particularly in the presence of known risk factors, such as alcohol, caloric excess and liver injury.
Predictive setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked) 
